From cell banks and processes to quality systems, Miracle Biomedical takes a platform approach to technology development and industry partnerships. A CommonWealth Magazine feature published on July 22, 2026 introduced this strategy and the parent company's direction in bringing regenerative medicine toward industrial development.
Making Quality and Processes a Foundation for Partnership
The value of regenerative medicine lies not only in research innovation, but also in the continued development of source management, process records and quality systems. Platform collaboration can connect these foundations with more research questions and industry partners, providing a stronger basis for technology development and partnership discussions.
Connecting Industry Experience with Animal Health Needs
Drawing on our parent company's emphasis on sourcing, processes and quality, Miracle Petgenix Biotech is advancing three directions: CDMO, veterinary drug development and FurNavi AI. Together, these connect research, veterinary collaboration and care records.
We look forward to working with veterinarians and industry partners, starting with clear clinical needs and embedding quality management, professional communication and continued follow-up into collaboration to build a stronger foundation for animal health.
Read the CommonWealth Feature ↗